≥30 kg / m 2
≥27 to < 30 kg / m 2 +
NOW AVAILABLE FOR CHRONIC WEIGHT MANAGEMENT 1
DID YOU KNOW ?
2 in 3
* Data from the Australian Bureau of Statistics National Health Survey 2022 . 2
Australian adults are living with overweight or obesity 2 *
Available to prescribe for Chronic Weight Management 1 †
in adults with an initial body mass index ( BMI ) of :
≥30 kg / m 2
OR
≥27 to < 30 kg / m 2 +
≥1 weight-related comorbid condition 1 ‡
† As an adjunct to a reduced-calorie diet and increased physical activity . Chronic Weight Management includes weight loss and weight maintenance . 1
‡ For example , hypertension , dyslipidaemia , obstructive sleep apnoea , cardiovascular disease , prediabetes or type 2 diabetes mellitus . 1
Hypothetical patient .
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management , including weight loss and weight maintenance , in adults with an initial body mass index ( BMI ) of ≥30 kg / m 2 ( obesity ) or ≥27 kg / m 2 to < 30 kg / m 2 ( overweight ) in the presence of at least one weight-related comorbid condition ( e . g ., hypertension , dyslipidaemia , obstructive sleep apnoea , cardiovascular disease , prediabetes or type 2 diabetes mellitus ). 1
BMI = body mass index ; CWM = Chronic Weight Management ; GIP = glucose-dependent insulinotropic polypeptide ; GLP-1 = glucagon-like peptide-1 ; HDL = high-density lipoprotein ; LDL = low-density lipoprotein ; LS = least squares ; mITT = modified intent-to-treat ; MMRM = mixed model for repeated measures ; MTD = maximum tolerated dose .
References : 1 . MOUNJARO ® Approved Product Information . 2 . Australian Institute of Health and Welfare . Overweight and Obesity . Available at : https :// www . aihw . gov . au / reports / overweight-obesity / overweight-and-obesity / contents / overweight-and-obesity Accessed October 2024 . 3 . Willard FS , et al . JCI Insight 2020 ; 5 ( 17 ): e140532 . 4 . Aronne LJ , et al . JAMA 2024 ; 331 ( 1 ): 38 – 48 ( including supplement ). 5 . Jastreboff AM , et al . N Engl J Med 2022 ; 387 ( 3 ): 205 – 16 ( including supplement ).